Metformin is a promising drug for cancer prevention and treatment, especially in the diabetic population. We aimed to test whether 14-3-3zeta affects the anticancer effect of metformin on colorectal carcinoma (CRC). In this study, we confirmed that higher 14-3-3zeta expression was found in CRC tissues than in pericarcinoma tissues, and in CRC tissue of patients with diabetes than in those without diabetes. A knockdown of 14-3-3zeta inhibited CRC proliferation and promoted apoptosis in vitro and in vivo. Then, we created stable cell lines with under-expressed 14-3-3zeta from SW480 and HCT15 cells after infection by a lentiviral vector carrying short hairpin RNA targeting 14-3-3zeta (named LV-sh14-3-3zeta). Of note, metformin induced apoptosis and retarded tumor growth in the CRCs with overexpressed 14-3-3zeta, whereas this action was attenuated when 14-3-3zeta was knocked down. Moreover, either metformin or downregulation of 14-3-3zeta noticeably activated AMP-dependent protein kinase (AMPK) signaling, whereas the effect of metformin was attenuated when the 14-3-3zeta expression was decreased. Taken together, our results suggest that 14-3-3zeta may be associated with carcinogenesis and poor prognosis of CRCs associated with diabetes, and metformin may reverse the AMPK inhibition caused by 14-3-3zeta in CRCs in the background of diabetes. Our study should lead to a better understanding of the anticancer activity of metformin and points to possible application of metformin to the treatment of cancers overexpressing 14-3-3zeta.
Introduction
Accumulating evidence has shown that diabetes mellitus (DM) is associated with an increased risk of various cancers (1) . In our previous work, 12 colon cancer samples were collected by surgical resection from diabetic patients, and 12 samples from nondiabetic patients with matched clinicopathological features were also selected. Isobaric tags for relative and absolute quantitation (iTRAQ)-based quantitative proteomic analysis revealed that the expression of 14-3-3zeta was obviously upregulated in colon cancer with diabetes, compared with colon cancer from nondiabetic patients (unpublished data). As shown in some reviews, patients with diabetes have higher serum levels of 14-3-3 than nondiabetic patients do (2) , and the 14-3-3 protein regulates Ask1 signaling, suppressing apoptosis and thereby limiting the progression of diabetic cardiomyopathy (3) . Besides, bioinformatic analysis has identified 17 diverse proteins related to 14-3-3 in diabetic mice (4) . Of the seven isoforms in the 14-3-3 family, 14-3-3zeta interacts with various key cellular proteins directly involved in the cancer initiation, development and progression, whereas overexpression of 14-3-3zeta has been reported to occur in a variety of cancers (5) . Thus, 14-3-3zeta is upregulated both in cancer and diabetes, implying its potential role in their interaction.
Metformin is a well-established effective agent widely used in the treatment of type 2 DM (T2DM), with a good safety profile and low cost (6) . Epidemiological studies have shown that metformin is a promising drug for cancer prevention and treatment (7) . Nonetheless, the association between metformin use and the risk and mortality of cancer depends on various population characteristics and types of cancer (8, 9) . It is reported that metformin is more effective in terms of tumor growth inhibition in the presence of diet-induced obesity and hyperinsulinemia (10) . We have previously reported that first-line chemotherapy with metformin, compared with insulin or other drugs, produces a better outcome in patients with non-small cell lung cancer and comorbid diabetes (11) . Metformin therapy decreases the risk of colorectal adenomas and colorectal cancer (CRC) in patients with T2DM (12) and increases overall survival among patients with CRC with pre-existing diabetes (13, 14) . In diabetic rats, metformin prevents dimethylhydrazine-induced CRC by reversing the Warburg effect (15) .
According to the available data to date, the anticancer effect of metformin seems more pronounced in a patient population with cancer and comorbid T2DM, whereas AMP-dependent protein kinase (AMPK) activation is believed to be the most important underlying mechanism (7) . A recent study showed that 14-3-3zeta prevents liver kinase B1 from phosphorylating its substrate, AMPK, and attenuates G1 cell cycle arrest and apoptosis (16) . In the present study, we aimed to investigate the role of 14-3-3zeta in CRC with diabetes and to test whether 14-3-3zeta affects the anticancer effect of metformin in CRC.
Materials and methods

Human CRC samples
Primary tumor samples of CRC had been retrospectively obtained from 244 patients with cancer who underwent radical surgical removal for local diseases in West China Hospital of Sichuan University during January 2009 to November 2011 and were acquired from formalin-fixed and paraffinembedded pathological samples from pathology department. One hundred fifty-five pericarcinoma colorectal tissues from the above-mentioned CRC tissues were extracted and analyzed. Among 244 patients with CRC, 122 participants were diabetic patients, and the other 122 were nondiabetics patients with paring principle from our previous report (17) . The use of the specimens was approved by Biomedical Ethics Committee of West China Hospital, Sichuan University.
Cell lines and antibodies
All colon cancer cell lines (LOVO, SW480, HCT116, HT29, SW620, HCT15, RKO and LIM1215) were purchased from American Type Culture Collection (ATCC, Manassas, VA). All cells were cultured in Dulbecco's Minimum Essential medium (DMEM; Hyclone, Logan, UT) with 10% fetal bovine serum, 100 μg/ml streptomycin and 100 U/ml penicillin at 37°C in 5% CO 2 .
Antibodies used in this study were as follows: 14-3-3zeta (C16, Santa Cruz, Dallas, TX), AMPKα (2532, CST, Boston, MA), Phospho-AMPKα (Thr172; 2531, CST), mechanistic target of rapamycin (mTOR; ab32028, Abcam, Hong Kong, China), Phospho-mTOR (Ser2448; 5536, CST), Cleaved Caspase 3 (9661, CST), Bcl-xl (ab32370, Abcam), Caspase 8 (ab184721, Abcam), Bax (ab32503, Abcam), Ki67 (ab15580, Abcam), PCNA (ab18197, Abcam), GAPDH (sc365062, Santa Cruz Biotechnology) and β-actin (sc-47778, Santa Cruz Biotechnology).
Animals
Four-week-old female BALB/c-nu nude mice were purchased from HFK bioscience Co., Ltd. (Beijing, China). Throughout the experiments, mice were maintained with free access to food and water. Animal welfare and experimental procedures were carried out strictly in accordance with institutional guidelines concerning animal use and care of Sichuan University.
Immunohistochemistry
Patient tumor samples were sectioned into 4 μm thick slices and subjected to immunohistochemical staining of the 14-3-3zeta protein with the Powervision method. After orderly deparaffinized in a series of xylene baths, then rehydrated using a graded alcohol series, and retrieved in sodium citrate buffer (pH 6.0) via microwave heating for 7 min at high fire, sections were incubated at 4°C overnight with an rabbit polyclonal anti-14-3-3zeta antibody (1:50, Santa Cruz Biotechnology). Later, PV6001 Two-Step immunohistochemistry Detection Reagent (ZSJQ-BIO, Beijing, China) covered the sections for 1 h at 37°C. Slides were color fixed by 3, 3'-diaminobenzidine (DAB) with hematoxylin counterstain. The intensity (intensity score: 0 negative, 1 weak, 2 moderate and 3 strong) plus percentage of positive tumor cells (proportion score: 0 < 10%, 10% ≤ 1 ≤ 33%, 34% ≤ 2 ≤ 66%, 67 ≤ 3 ≤ 100%) was evaluated for each specimen for scoring 14-3-3zeta expression (18) .
Immunohistochemical staining in mouse xenograft model was performed on 4 μm tissue sections from paraffin embedded tissue blocks from tumor xenografts. Anti-Cleaved Caspase3 (CST), Anti-Ki-67 (Abcam) and anti-PCNA (Abcam) were used for detection. Positively stained nuclei in cells were counted and positive percentages were calculated across six high-power fields (400) in three tumor samples each group for evaluation of the immunostaining.
Transfection of siRNA
Three different predesigned siRNA sequences targeting 14-3-3zeta were obtained from Shanghai GenePharma Co., Ltd, China. These sequences are as follows: siRNA1, GCUAAGAGAUAUCUGCAAUtt (sense) and AUUGCAGAUAUCUCUUAGCtt (antisense); siRNA2, GCACGCUAAU AAUGCAAUUtt (sense) and AAUUGCAUUAUUAGCGUGCtt (antisense); siRNA3, GCUAAGAGAUAUCUGCAAUtt (sense) and AUUGCAGAUAUCU CUUAGCtt (antisense). Negative control siRNA: UUCUCCGAACGUGUCA CGUTT (sense) and ACGUGACACGUUCGGAGAATT (antisense), and Cy3-labeled control siRNA for determining transfection efficiency were also obtained from GenePharma. Transient transfection of siRNAs was done using X-tremeGENE siRNA Transfection Reagent (Roche, Shanghai, China) following the manufacturer's instructions. Briefly, CRC cells were seeded at a density of 2 × 10 5 per well in six-well plates for 24 h. siRNAs (µg): X-tremeGENE (µl) was seted as two different concentration ratios, 2:10 or 6:30, respectively. SiRNAs were diluted in 100 μl of Opti-MEM and combined with X-tremeGENE mixed in 100 μl of Opti-MEM. The mixture was incubated at room temperature for 20 min and then added to the plated cells. Complete medium replaced transfection medium after 6 to 8 h. The transfected cells were collected for further analyses at 72 h after transfection. Generation of stable short-hairpin siRNA (shRNA)
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14-3-3zeta infectants
To establish stable SW480 and HCT15 cell lines expressing sh14-3-3zeta, 14-3-3zeta shRNA lentiviral particles (LV-sh14-3-3zeta) and shRNA negative control lentiviral particle (LV-shNC) were purchased from GenePharma, Shanghai, China. To generate stable cells, SW480 or HCT15 cells were plated in twelve-well plates (1 × 10 5 cells per well), transduced with 100 MOI lentiviral particles [using 5 µg/µl polybrene (Sigma, Shanghai, China)]. Three days after infection, cells were selected in 1 µg/ml puromycin (Sigma) and green fluorescence could be observed in infected cells using an Olympus BX600 microscope. Suppression of 14-3-3zeta in stable cells was confirmed by western blot analysis.
Western blot analysis
Briefly, cells were lysed by the RIPA lysis buffer (Beyotime, Nanjing, JS, China) containing 1% protease inhibitor cocktail (Merck Millipore, Hong Kong, China). The Bradford protein assay kit (Thermo Scientific, MA) was employed to determine the protein concentrations. Equal amounts of proteins (25-30 μg) from cells were resolved on SDS-polyacrylamide gels. After separated proteins electrotransferred onto PVDF membranes (Merck Millipore) and then blocked with 5% nonfat powdered milk in 0. 
Cell proliferation assay
Cell growth and viability was estimated using the Cell Counting kit-8 (Dojindo, Kumamoto, Japan) assay. CRC cells were transfected with siRNA targeting 14-3-3zeta or siRNA control in six-well plates for 24 h and then plated in triplicates in 96-well plates at a density of 10 4 cells/well in complete medium. After cells were observed for 72 h, CCK-8 reagent was added (10 µl/well) and incubation continued for 2 h. 
Apoptosis assay
siRNA-transfected cells and stable cells after treatment of metformin for 72 h were collected. Apoptosis was detected by Annexin V-FITC/ propidium iodide (PI) staining (BD BioSciences, Shanghai, China) for common cells or Annexin V-APC/7-AAD staining (keyGEN BioTECH, Nanjing, JS, China) for cells with green fluorescene proteins according to the manufacturer's instructions. In brief, cells were trypsinized, pelleted by centrifugation (1,500 rpm for 5 min) and resuspended in Annexin V-binding buffer. Annexin V-FITC and PI (or Annexin V-APC and 7-AAD) were added to cells and incubated for 15 min at room temperature in the dark. Analyses were done on facScalibur systems (Beckman Coulter, USA; NovoExpress, USA) and the relevant analysis softwares.
Cell cycle analysis using flow cytometry
Cells were fixed in ice-cold 70% ethanol and stained with propidium iodide (50 mg/ml in PBS; Sigma) in the presence of RNAse (100 mg/ml) using a facScalibur system (NovoExpress, USA). The percentage of cells in various phases of the cell cycle was calculated using the NovoExpress® software.
CRC xenografts in nude mice
4 × 10 6 infected SW480 cells suspended in serum-free Dulbecco's Minimum Essential medium were injected subcutaneously into the right flank of 5-to 6-week-old athymic nude mice. After tumor establishment (50-100 mm 3 ), mice were treated with metformin (250 mg/kg/daily oral gavage) or drinking water by oral gavage served as control. Each group consisted of six mice. Animals injected by LV-shNC-infected cells were killed when tumors achieved about 2500 mm 3 in size on day 43. Animals injected by LV-sh14-3-3zeta infected cells were killed on day 95. Tumor volume was measured twice a week using vernier caliper. Tumor volume was calculated by using the formula length × width × width/2. After animals were killed, tumors were rapidly removed and then fixed in 10% formalin, embedded in paraffin, and subjected to Ki67, PCNA staining and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) analyses.
TUNEL assay
TUNEL assay kit was from Roche Applied Systems. TUNEL assay was done following the manufacturer's instructions. To detect TUNEL-positive signals, the slides were incubated with DAB substrate with hematoxylin counterstain. The slides were then examined and the images were recorded using an Olympus BX600 microscope and SPOT Flex camera. Dark brown staining represented a positive reaction. DAB-positive (DAB+) and hematoxylin positive (hematoxylin+) cells were counted at ×400 magnification. Apoptosis index was defined as DAB+/hematoxylin+ cells in random six fields per section for quantification.
Statistical analysis
All experiments were repeated for three times and the results of multiple observations are presented as the means ± SD. Statistical analysis of the data was carried out using the SPSS 17.0 software. Chi-square test was used to compare 14-3-3zeta expression in two groups. The Student's t-tests was used for comparing two groups. ANOVA was applied to compare growth rates of tumors in two groups. A probability P < 0.01 was considered to be statistically significant.
Results
14-3-3zeta overexpression in human CRC tissues from patients with pre-existing diabetes
To investigate the expression characteristics of 14-3-3zeta in CRC, immunohistochemistry pictures are presented in a group of tumors and pericarcinoma tissues and in tumors groups with or without diabetes, as shown in Fig. 1 . Expression of the 14-3-3zeta protein was observed both in tumors and pericarcinoma tissues, mainly in the cytoplasm of cells. In addition, we found stronger expression of 14-3-3zeta in CRCs (194/244, 79.5%) compared with pericarcinoma control tissues (34/155, 21.9%), P < 0.001 (Table 1) . We further analyzed 14-3-3zeta expression in CRC tissues from patients with pre-existing diabetes and those from matched nondiabetic control patients. Higher expression of 14-3-3zeta was observed in CRCs from patients with preexisting diabetes (63.1%), compared with nondiabetic controls (44.3%), P = 0.003 (Table 1 ). This result suggests that 14-3-3zeta may be involved in CRC carcinogenesis, especially in diabetesrelated CRC carcinogenesis.
CRC cells with various 14-3-3zeta expression levels react differently to metformin
Western blotting analysis was performed to detect and quantify 14-3-3zeta protein expression in eight CRC cell lines as mentioned above. Among the eight CRC cell lines, HCT15 and SW480 cells were found to have relatively high expression of 14-3-3zeta, whereas HCT116 and RKO cells have relatively low expression of 14-3-3zeta ( Fig. 2A) . We analyzed sensitivity of these four CRC cell lines to metformin. These cell lines were incubated with various concentrations of metformin for 72 h. The cell viability was decreased after metformin treatment in the following order: HCT15, SW480, RKO, HCT116 (Fig. 2B) . IC 50 values of metformin at 72 h were 14.03 ± 1.39, 26.74 ± 0.21, 32.50 ± 3.32 and 36.08 ± 1.61 mM, respectively, in HCT15, SW480, RKO and HCT116 cells (Fig. 2C) . It seems that the CRC cells with higher 14-3-3zeta expression showed a better response to metformin than those with lower 14-3-3zeta expression levels.
Effects of decreased 14-3-3zeta expression on cell proliferation, apoptosis and the cell cycle
Transfection efficiency of three siRNAs in SW480 cells is shown in Fig. 2D . A CCK-8 assay showed inhibition of cell proliferation in SW480 (20.4% ± 2.5%, P < 0.001) and HCT15 cells (22.3% ± 3.5%, P < 0.001) transfected with si14-3-3zeta at 72 h relative to negative controls (Fig. 2E) . Western blot analysis indicated that expression of Cleaved Caspase 3 significantly increased when 14-3-3zeta was downregulated by siRNA2 and siRNA3 in SW480 and HCT15 cells (Fig. 2F ). An annexin V assay revealed more apoptosis in SW480 (16.9% ± 1.8%, P < 0.01) and HCT15 cells (26.8% ± 1.6%, P < 0.01) during depletion of 14-3-3zeta compared with negative controls (8.1% ± 1.2% and 12.6% ± 2.9%, respectively; Fig. 2G ). Cell cycle analysis showed an increased G1 proportion at 72 h in SW480 (58.5% ± 1.5%, P < 0.01) and HCT15 cells (49.1% ± 1.0%, P < 0.001) transfected with si14-3-3zeta in contrast to negative controls (50.8% ± 1.1% and 38.8% ± 1.1%, respectively; Fig. 2H ). Taken together, these data indicated that 14-3-3zeta is involved in proliferation, apoptosis and cell cycle regulation in CRC.
Metformin-induced apoptosis was attenuated after inhibition of 14-3-3zeta expression
LV-shNC-or LV-sh14-3-3zeta-infected cells (parental cell lines: SW480 and HCT15) were treated with 10 mM metformin, respectively, to measure sensitivity to metformin. Western blotting confirmed weak 14-3-3zeta expression and high Cleaved Caspase 3 expression in LV-sh14-3-3zeta-infected SW480 and HCT15 stable cell lines and metformin-treated SW480 and HCT15 cells, with the LV-shNC-infected cells serving as a control (Fig. 3A) . Apoptotic cell death was measured by annexin V-APC/7-AAD double staining. Increased apoptosis was well pronounced in metformin-treated LV-shNC (SW480/HCT15) cells compared with metformin-untreated cells as well as in LV-sh14-3-3zeta (SW480/HCT15) cells compared with LV-shNC cells, as shown in Fig. 3B-D . By contrast, no significant difference in apoptosis was observed in SW480/HCT15 cells infected with LV-sh14-3-3zeta between metformin treatment and control, suggesting that the decreased effect of metformin on CRC may be related to the weak expression of 14-3-3zeta. 
Decreased 14-3-3zeta expression influenced the tumor inhibition rate of metformin in SW480 tumor xenografts
To examine the possible association between therapeutic effectiveness of metformin and 14-3-3zeta expression levels, a nude-mouse model of xenograft CRC was employed. LV-shNCor LV-sh14-3-3zeta-infected SW480 stable cell lines (SW480-LVshNC or SW480-LV-sh14-3-3zeta) were injected into the flank region of nude mice. After palpable tumors formed, one group was treated with metformin in drinking water and the other received regular drinking water every day. Tumor growth was measured by calculating tumor volume for 3-4 days. Animals injected with SW480-LV-shNC cells were euthanized when tumors reached ~2,500 mm 3 in size on day 43. Animals injected with SW480-LVsh14-3-3zeta cells were euthanized on day 95. After treatment for 36 days, a slower tumor growth rate was observed in metformintreated mice having SW480-LV-shNC tumor xenografts (Fig. 4A) . Among SW480-LV-sh14-3-3zeta tumor xenografts, we observed that tumors had a longer interval to formation and especially an obviously slower growth rate (Fig. 4A) . Nevertheless, after 69 days of administration of metformin in the SW480-LV-sh14-3-3zeta group, the tumor growth rate did not decline (Fig. 4A) . After 36-day treatment with metformin, tumor volumes decreased, with the mean inhibition rate of 40.2% among SW480-LV-shNC tumors, P < 0.001, but this decrease was not obvious among the SW480-LV-sh14-3-3zeta tumors: the mean inhibition rate of 34.2%, P = 0.031 (Fig. 4B ). All the above results indicated that metformin had an antitumor effect on CRC with overexpressed 14-3-3zeta but showed relatively low efficacy against tumors with underexpressed 14-3-3zeta.
Metformin suppressed proliferation and promoted apoptosis of tumors in vivo, but the effect was relatively attenuated in tumors with underexpressed 14-3-3zeta
To examine the effect of metformin on apoptosis and proliferation at the tissue level, animals were euthanized after treatment with metformin for 36 days, and tumor tissues were rapidly paraffin-embedded for a TUNEL assay and Western blot analysis showed a significant decrease of 14-3-3zeta in SW480, especially transfected with siRNA1 and siRNA2 at the second concentration ratio (decrease >80%). GAPDH served as a loading control. (E) CCK8 assay showed relative inhibition of cell proliferation in SW480 (***P < 0.001) and HCT15 (***P < 0.001) cells tranfected in 72 h to negative control.
(F) Western blot analysis evaluated that expression of Cleaved Caspase 3 showed significant activation, whereas 14-3-3zeta was downregulated in SW480 and HCT15.
β-actin served as a loading control. (G) Annexin V assay revealed more apoptosis in SW480 (**P < 0.01) and HCT15 (**P < 0.01) cells in the depletion of 14-3-3zeta. (H) Cell cycle analysis showed increased G1 fraction in 72 h in SW480 (**P < 0.01) and HCT15 (***P < 0.001) transfected with si14-3-3zeta compared with negative controls. si14-3-3zeta 2 was mainly used for these experiments. CRC colorectal cancer; Met metformin; h hours; si14-3-3zeta siRNAs directed against 14-3-3zeta; siNC scramble negative control siRNA.
immunohistochemical analysis of Cleaved Caspase 3, Ki67 and PCNA. Representative images are presented in Fig. 4C . Histological analysis of tumor tissues showed statistically significant differences in the percentage of Cleaved Caspase 3-, TUNEL-, Ki67-and PCNA-positive cells between mice with SW480-LV-shNC tumors treated with metformin and mice that received regular drinking water (Fig. 4D-G) . Likewise, distinctly greater numbers of Cleaved Caspase 3-and TUNEL-positive cells and lower numbers of Ki67-and PCNA-positive cells were found in SW480-LV-sh14-3-3zeta tumors compared with a negative control (Fig. 4D-G) . Moreover, treatment with metformin did not significantly increase numbers of TUNEL-and Cleaved Caspase 3-positive cells or decrease the numbers of Ki67-and PCNApositive cells in SW480-LV-sh14-3-3zeta tumors (Fig. 4D-G) . These data suggested that decreased 14-3-3zeta expression may facilitate cell apoptosis and suppress tumor growth, and in 14-3-3zeta-overexpressing CRCs, reduced tumor growth after metformin treatment may be caused by increased apoptosis and proliferation inhibition, whereas the effect of metformin was less obvious in tumors with low expression of 14-3-3zeta. HCT15) were treated 10mM metformin, respectively, for 72 h to measure sensitivity to metformin. Apoptotic cell death was measured by FACS analysis using Annexin-APC 7-AAD doublestaining. Data are presented as mean ± SD. **P < 0.01, ***P < 0.001 vs. LV-shNC; †P ˃ 0.01 vs. LV-sh14-3-3zeta. Met metformin; mM mmol/l; h hours; LV-sh14-3-3zeta cells transfected by 14-3-3zeta shRNA lentiviral particles; LV-shNC cells transfected by negative control shRNA lentiviral particle.
Metformin attenuated the AMPK and apoptosis inhibition caused by 14-3-3zeta
To identify the potential mechanism via which 14-3-3zeta participates in the anticancer effect of metformin, a western blot was carried out to examine the expression of AMPK signaling proteins and apoptosis-associated proteins in SW480-LV-shNC and SW480-LV-sh14-3-3zeta cells at different time points: after 24, 48 and 72 h of treatment with metformin. The results indicated that in cells with high 14-3-3zeta expression, metformin treatment dramatically increased AMPK phosphorylation and reduced mTOR phosphorylation. Furthermore, in cells with decreased 14-3-3zeta expression, strong activation of AMPK was well detectable along with inhibited mTOR activation; however, metformin caused only slight upregulation of AMPK phosphorylation after the longer treatment (72 h) as shown in Fig. 5A . These data suggest that after the knockdown of 14-3-3zeta, AMPK signaling strongly increased and then further activation of AMPK signaling by metformin was attenuated with prolonged treatment. Besides, we detected Bax, Cleaved Caspase 8, and Cleaved Caspase 3 upregulation, and downregulation of the prosurvival protein Bcl-xl in CRC cells after metformin exposure. On the other hand, in cells with underexpressed 14-3-3zeta, metformin caused only relatively moderate changes in the expression of apoptosis-associated proteins, especially Bcl-xl, after 72 h treatment (Fig. 5B) . These results illustrate that metformin promotes apoptosis through activation of mitochondriaassociated apoptosis proteins, and this effect is more obvious in CRC with overexpressed 14-3-3zeta.
Discussion
In our study, higher 14-3-3zeta expression was found in human CRC tissues from patients with pre-existing diabetes by immunohistochemical analysis compared with the nondiabetic control CRC tissues, in accordance with our findings in the iTRAQ assay (unpublished data). 14-3-3zeta protein expression has been reported to be higher in colon cancer (19) . Nevertheless, to date, the participation of 14-3-3zeta in CRC is unclear. In our study, stronger expression of 14-3-3zeta was found in human CRC tissues compared with pericarcinoma control tissue, suggesting that 14-3-3zeta may play some role in carcinogenesis. Our experiments in vitro and in vivo later showed that a knockdown of 14-3-3zeta in CRCs inhibited proliferation, increased apoptosis, prolonged the interval to tumor formation and dramatically slowed the growth rate of tumors; these findings point to the potential involvement of 14-3-3zeta in CRC. Similar results were reported in other studies; for example, 14-3-3zeta downregulation inhibits proliferation and activates anoikis in lung cancer cells (20) , whereas downregulation of 14-3-3zeta in breast cancer suppresses anchorage-independent growth, promotes stress-induced apoptosis and reduces tumor growth in vivo (21) . These studies support our finding that 14-3-3zeta may participate in CRC formation and progression, especially in the background of diabetes. Thus, our results should lead to a better understanding of the higher risk of CRC and poorer prognosis of CRC in the diabetic population.
Overwhelming evidence from in vitro and in vivo models of carcinogenesis and epidemiological studies support the potential antitumor efficacy of metformin. Low-dose metformin decreased the prevalence and number of metachronous adenomas or polyps in postpolypectomy patients in a multicenter double-blind, placebo-controlled, randomized phase III trial (22) . Basic experimental studies also showed that metformin inhibits proliferation and induces apoptosis in colon cancer (23) . Further studies revealed that metformin decreases the risk of CRC and the associated mortality in patients with T2DM (12) (13) (14) . On the other hand, there are some conflicting reports about the link of metformin to CRC. Some reports indicate that metformin is not related to a reduced risk of CRC (24). Sui's study did not detect an anticancer effect of metformin alone on CRC cells including HCT116, HT-29 and RKO cells (25) . Moreover, our experiments suggest that CRC cell lines with overexpressed 14-3-3zeta (such as HCT15 and SW480) are more sensitive to metformin, whereas those with underexpressed 14-3-3zeta (such as HCT116 and RKO) are less sensitive to metformin. These data are in agreement with Sui's study and suggest that 14-3-3zeta expression may be relevant to the efficacy of metformin. We next created stable cell lines underexpressing 14-3-3zeta from SW480 and HCT15 cells infected by LV-sh14-3-3zeta. Of note, no notable apoptosis-promoting or growth-inhibitory effect was observed in CRCs with underexpressed 14-3-3zeta in vitro and in vivo after prolonged treatment with metformin. In contrast, metformin exerted its obvious anticancer effect in the control group with overexpressed 14-3-3zeta. Therefore, these results imply that upregulation of 14-3-3zeta causes sensitivity to metformin, and this notion may explain the better outcome of metformin treatment among CRC patients with diabetes.
14-3-3zeta is reported to take part in the regulation of many metabolic pathways, thus modulating cellular and whole-body energy and nutrient homeostasis (26) . We found that the 14-3-3zeta knockdown enhanced phosphorylation of AMPK and downregulated phosphorylation of mTOR, and these data seem to be supported by Bai's study (16) . Metformin also activated AMPK and inhibited mTOR, but its effect was attenuated when AMPK was highly activated and functional under the influence of the 14-3-3zeta knockdown. Algire (10) and Shackelford (27) demonstrated that biguanides are more effective against cancers with low functioning of the liver kinase B1-AMPK pathway in animal models. Likewise, we found that CRCs with 14-3-3zeta overexpression and the inhibited AMPK pathway are more sensitive to metformin, suggesting that metformin may reverse the AMPK inhibition caused by high expression of 14-3-3zeta. Therefore, our study supports the anticancer effect of metformin during diabetes as reported in other studies and points to possible application of metformin to the treatment of cancers with high expression of 14-3-3zeta, even in patients without diabetes.
Our study also shows that metformin alone induced apoptosis by activation of Bax, Cleaved Caspase 8 and Cleaved Caspase 3 and via inhibition of Bcl-xl expression in CRCs; these findings may be supported by the reports about other cancers, such as epithelial ovarian cancer (28) and pancreatic cancer (29) . Besides, we found that the action of metformin was attenuated in 14-3-3zeta-underexpressing cells. Generally, 14-3-3 participates in apoptosis by interacting with BH3 domain-containing proteins of the Bcl-2 family, particularly Bad and Bax (30). 14-3-3 facilitates inactivation of Bad to stop it from binding to and inactivating the prosurvival protein Bcl-xl (31), in line with our observation that downregulation of 14-3-3zeta promoted apoptosis through the changes in expression of mitochondriaassociated apoptosis signaling molecules. Furthermore, in our study, metformin did not exert its action effectively when the mitochondria-associated apoptosis signaling was highly activated by downregulation of 14-3-3zeta.
In conclusion, we for the first time found that 14-3-3zeta expression correlates with CRC in patients with pre-existing diabetes and that the 14-3-3zeta knockdown inhibits CRC proliferation and promotes apoptosis in vitro and in vivo, suggesting that 14-3-3zeta may participate in carcinogenesis associated with diabetes. Moreover, our study revealed a novel effect of metformin: it induces apoptosis and retards tumor growth in CRCs with overexpressed 14-3-3zeta, whereas this action is impaired when 14-3-3zeta is knocked down, implying that 14-3-3zeta may be involved in the anticancer effect of metformin in CRC. The possible mechanism is related to AMPK signaling affected by both the 14-3-3zeta knockdown and metformin. Our study should advance the understanding of the high risk of CRC and the associated mortality (as well as anticancer activity of metformin) in the diabetic population. Our data also imply that metformin may be applied to the treatment of cancer with 14-3-3zeta overexpression. Therefore, to confirm the population suitable for metformin application to cancer treatment, further research on 14-3-3zeta and metformin would be necessary.
